• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与 COVID-19 后综合征相关的证据为旁观者 T 细胞激活和反复发生的抗生素耐药性细菌性肺炎。

Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia.

机构信息

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

North Bristol NHS Trust, Bristol, United Kingdom.

出版信息

Elife. 2020 Dec 17;9:e63430. doi: 10.7554/eLife.63430.

DOI:10.7554/eLife.63430
PMID:33331820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7775105/
Abstract

Here, we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by that acquired increasing levels of antimicrobial resistance (AMR) in response to treatment. Metagenomic analysis revealed the AMR genotype, while immunological analysis revealed massive and escalating levels of T-cell activation. These were both SARS-CoV-2 and specific, and bystander activated, which may have contributed to this patient's persistent symptoms and radiological changes.

摘要

在这里，我们描述了一例 COVID-19 患者的情况，该患者因治疗而导致获得性抗菌药物耐药性（AMR）不断增加，从而反复发生呼吸机相关性肺炎。宏基因组分析揭示了 AMR 基因型，而免疫分析揭示了大量和不断升级的 T 细胞激活。这些都是 SARS-CoV-2 和 的特异性和旁观者激活的，这可能导致了该患者持续的症状和影像学改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/c4f2856cf204/elife-63430-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/df88d03ebdd7/elife-63430-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/3053925b0f04/elife-63430-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/3a919656dfe0/elife-63430-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/bffecc76a277/elife-63430-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/784a06fcd486/elife-63430-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/c501b4abdfa0/elife-63430-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/075b74f949fc/elife-63430-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/3e914203b4fb/elife-63430-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/c4f2856cf204/elife-63430-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/df88d03ebdd7/elife-63430-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/3053925b0f04/elife-63430-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/3a919656dfe0/elife-63430-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/bffecc76a277/elife-63430-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/784a06fcd486/elife-63430-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/c501b4abdfa0/elife-63430-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/075b74f949fc/elife-63430-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/3e914203b4fb/elife-63430-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5778/7775105/c4f2856cf204/elife-63430-fig4-figsupp1.jpg

相似文献

1
Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia.与 COVID-19 后综合征相关的证据为旁观者 T 细胞激活和反复发生的抗生素耐药性细菌性肺炎。
Elife. 2020 Dec 17;9:e63430. doi: 10.7554/eLife.63430.
2
A Combination Antibiogram Evaluation for in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals.美国医院 ICU 和非 ICU 环境下呼吸和血液来源的 联合抗生素药敏评价。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02564-18. Print 2019 Apr.
3
Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland.瑞士 COVID-19 患者呼吸道革兰氏阴性细菌分离株的药敏模式。
Ann Clin Microbiol Antimicrob. 2021 Sep 7;20(1):64. doi: 10.1186/s12941-021-00468-1.
4
Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa.雾化吸入亚胺培南以控制铜绿假单胞菌引起的医院获得性肺炎。
J Crit Care. 2008 Mar;23(1):148-50. doi: 10.1016/j.jcrc.2007.10.037.
5
Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.雾化头孢他啶和阿米卡星治疗铜绿假单胞菌引起的呼吸机相关性肺炎。
Am J Respir Crit Care Med. 2011 Jul 1;184(1):106-15. doi: 10.1164/rccm.201011-1894OC. Epub 2011 Apr 7.
6
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).新型β-内酰胺/β-内酰胺酶抑制剂组合对来自美国医疗中心的铜绿假单胞菌分离株的比较活性（2020 - 2021年）
Int J Antimicrob Agents. 2023 Apr;61(4):106744. doi: 10.1016/j.ijantimicag.2023.106744. Epub 2023 Feb 3.
7
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.2013 年至 2015 年期间，美国住院患者呼吸道标本中分离的铜绿假单胞菌和肠杆菌科细菌对头孢他洛滨-他唑巴坦的活性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02125-17. Print 2018 Mar.
8
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.头孢洛扎/他唑巴坦治疗严重铜绿假单胞菌感染的多中心全国临床经验。
Int J Antimicrob Agents. 2019 Apr;53(4):408-415. doi: 10.1016/j.ijantimicag.2018.11.001. Epub 2018 Nov 8.
9
The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.呼吸标本中携带多重耐药铜绿假单胞菌的肺炎患者的临床意义：4 个综合 ICU 中 5667 例患者 5 年回顾性研究。
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2155-2163. doi: 10.1007/s10096-017-3039-z. Epub 2017 Jun 17.
10
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.头孢洛扎/他唑巴坦治疗多重耐药铜绿假单胞菌引起的呼吸道感染
Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28.

引用本文的文献

1
Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.双重威胁：新型冠状病毒肺炎与细菌合并感染的易感性机制及治疗策略
Comput Struct Biotechnol J. 2025 May 22;27:2107-2122. doi: 10.1016/j.csbj.2025.05.033. eCollection 2025.
2
Antimicrobial, antibiofilm, and antiviral investigations using egyptian phoenix dactylifera L. pits extract.使用埃及海枣核提取物进行的抗菌、抗生物膜和抗病毒研究。
AMB Express. 2024 May 9;14(1):44. doi: 10.1186/s13568-024-01695-3.
3
Coronavirus disease 2019 (COVID-19)-associated brain abscesses caused by Pseudomonas aeruginosa and Aspergillus fumigatus: two case and a review of the literature.

本文引用的文献

1
Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort.COVID-19 住院患者的预后及其随访意义：来自英国前瞻性队列研究的结果。
Thorax. 2021 Apr;76(4):399-401. doi: 10.1136/thoraxjnl-2020-216086. Epub 2020 Dec 3.
2
Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.在 COVID-19 之后，英国康复个体中 SARS-CoV-2 诱导产生的广泛而强大的记忆性 CD4 和 CD8 T 细胞。
Nat Immunol. 2020 Nov;21(11):1336-1345. doi: 10.1038/s41590-020-0782-6. Epub 2020 Sep 4.
3
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
COVID-19 相关脑脓肿由铜绿假单胞菌和烟曲霉引起：两例病例及文献复习。
J Med Case Rep. 2023 Dec 4;17(1):520. doi: 10.1186/s13256-023-04206-3.
4
Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach.重症 COVID-19 患者体内靶向心磷脂和血小板糖蛋白的自身抗体水平随年龄升高：一种系统生物学方法
NPJ Aging. 2023 Aug 24;9(1):21. doi: 10.1038/s41514-023-00118-0.
5
Hematological alterations associated with long COVID-19.与新冠长期症状相关的血液学改变。
Front Physiol. 2023 Jul 24;14:1203472. doi: 10.3389/fphys.2023.1203472. eCollection 2023.
6
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months.T 细胞持续激活和长新冠症状与 3 个月时的重症 COVID-19 独立相关。
Elife. 2023 Jun 13;12:e85009. doi: 10.7554/eLife.85009.
7
Long COVID: a narrative review of the clinical aftermaths of COVID-19 with a focus on the putative pathophysiology and aspects of physical activity.长新冠：对新冠病毒感染临床后果的叙述性综述，重点关注假定的病理生理学和身体活动方面。
Oxf Open Immunol. 2022 Sep 16;3(1):iqac006. doi: 10.1093/oxfimm/iqac006. eCollection 2022.
8
Role of T cells in severe COVID-19 disease, protection, and long term immunity.T 细胞在严重 COVID-19 疾病、保护和长期免疫中的作用。
Immunogenetics. 2023 Jun;75(3):295-307. doi: 10.1007/s00251-023-01294-9. Epub 2023 Feb 8.
9
Incidence, Outcomes and Risk Factors of Recurrent Ventilator Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study.新型冠状病毒肺炎患者复发性呼吸机相关性肺炎的发病率、结局及危险因素：一项回顾性多中心研究
J Clin Med. 2022 Nov 30;11(23):7097. doi: 10.3390/jcm11237097.
10
Prevention and treatment of ventilator-associated pneumonia in COVID-19.新型冠状病毒肺炎中呼吸机相关性肺炎的防治
Front Pharmacol. 2022 Oct 19;13:945892. doi: 10.3389/fphar.2022.945892. eCollection 2022.
COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
4
SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential.严重急性呼吸综合征冠状病毒2特异性T细胞表现出辅助功能的表型特征、缺乏终末分化且具有高增殖潜力。
Cell Rep Med. 2020 Sep 22;1(6):100081. doi: 10.1016/j.xcrm.2020.100081. Epub 2020 Aug 19.
5
Management of post-acute covid-19 in primary care.初级保健中新冠后急性期的管理。
BMJ. 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026.
6
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.COVID-19 患者的细菌合并感染和继发感染：一项实时快速综述和荟萃分析。
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016. Epub 2020 Jul 22.
7
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications.深度免疫剖析 COVID-19 患者，揭示具有治疗意义的不同免疫类型。
Science. 2020 Sep 4;369(6508). doi: 10.1126/science.abc8511. Epub 2020 Jul 15.
8
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
9
A serological assay to detect SARS-CoV-2 seroconversion in humans.用于检测人类 SARS-CoV-2 血清转化的血清学检测方法。
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.
10
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.人类中的新型冠状病毒2型血清转化：血清学检测、抗原生产及试验设置的详细方案
Curr Protoc Microbiol. 2020 Jun;57(1):e100. doi: 10.1002/cpmc.100.